The UC Davis Cancer Center Biorepository was created in 2004 to provide quality cancer-related human biospecimens that are procured, stored and annotated using international standards of best practices and protocols that are Office for Human Research Protection (OHRP) compliant. The biorepository functions as a centralized tissue bank that provides all cancer center members with an efficient, high quality, stable, reliable, cost-effective access to cancer-related specimens and histology services.
The specific aims of the Biorepository shared resource are: The primary objectives of the CCB shared resource are to facilitate cancer related research at UC Davis by 1 procuring, preparing, storing and dispersing human cancer-related biospecimens from a centralized cancer center biorepository; 2 providing pathological and clinical annotated data using a secure database (caTissue) 3 ensuring compliance with all mandated regulatory processes (HHS, IRB, HIPAA, SRC) thereby promoting ethical research by UC Davis researchers; 4 providing experienced pathologic consultation to investigators 5 efficiently prioritizing, tracking and dispersing biospecimen requests via a rapid, web-based approval and monitoring process 6 providing Tissue Microarray (TMA) construction and histology services for Cancer Center investigators The long-term objective of the CCSR is to facilitate scientific interactions and enhance scientific productivity by providing well-characterized, high-quality cancer-related specimens with annotated data for clinical and basic science research purposes.
The resource provides tissue in various forms of storage as well as bodily fluids that are used in basic cancer research and in animal models of cancer to improve scientific understanding of tumors, tumor development, and anti-tumor therapies with benefit, ultimately, to how cancer patients are treated and cured of disease.
|Zhong, Cheng; Han, Ju; Borowsky, Alexander et al. (2017) When machine vision meets histology: A comparative evaluation of model architecture for classification of histology sections. Med Image Anal 35:530-543|
|Zeng, Shu-Xiong; Zhu, Yanjun; Ma, Ai-Hong et al. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res 23:6580-6591|
|Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67|
|Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32|
|Yap, Stanley A; Yuh, Lindsay M; Evans, Christopher P et al. (2017) Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol 35:277-283|
|York, D; Sproul, C D; Chikere, N et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol :|
|(2017) New and emerging developments in extensive-stage small cell lung cancer therapeutics: Erratum. Curr Opin Oncol 29:88|
|Johnson, Lianna M; Du, Jiamu; Hale, Christopher J et al. (2017) Corrigendum: SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature 543:136|
|Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755|
|Wan, Debin; Yang, Jun; Barnych, Bogdan et al. (2017) A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine. J Lipid Res 58:798-808|
Showing the most recent 10 out of 733 publications